Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

Goldman Sachs Buy upgrade, citing growth potential from sovereign AI and customized software applications, has helped drive Palantir shares to fresh highs. Bulls are celebrating the momentum and speculating about a short squeeze, while bears warn that the valuation is stretched and the rally could reverse.

Modernas Nasdaq-100 reentry and expected index-fund buying, alongside optimism about a planned NIH cancer-vaccine initiative and the companys personalized cancer-vaccine program, are driving attention. Traders debate whether the surge reflects durable pipeline prospects or temporary index flows and momentum, with skeptics pointing to the companys losses and valuation.

SpaceXs planned acquisition of Grain Managements 800 MHz spectrum has fueled concern that Starlink will become a stronger competitor in satellite-to-phone connectivity, weighing on ASTS shares. Traders are split: bears see a threat to ASTSs position, while bulls argue SpaceXs push into wireless could strengthen ASTSs role as a satellite partner to carriers, whose spectrum access the CEO has highlighted.

GameStops strong advance toward a 52-week high and breakout momentum are driving attention, with traders anticipating a possible short or options-driven squeeze. Excitement over potential gamma effects and rumored Ryan Cohen or Roaring Kitty developments is countered by skepticism that the rally lacks a confirmed catalyst and could fade or face dilution.

SpaceXs agreement to acquire Grain Managements 800 MHz spectrum portfolio has stoked concern that Starlink Mobile could become a competitor to established wireless carriers, contributing to T-Mobiles sharp selloff. Traders are split between viewing the deal as a long-term threat and calling the reaction excessive given the infrastructure, capacity and time needed to build a competitive network.

Novavax is drawing attention around the Sanofi Phase 3 COVID-flu combination trial, whose EU authorization and potential milestone payment have bolstered interest in the partnership and Matrix-M platform. Traders also debate whether a Russian suspected-plague scare and broader vaccine-sector momentum amplified the rally, while many frame the move as a possible short squeeze and caution that the outbreak link is unverified.

TG Therapeutics announced MSToronto 2026 data presentationsparticularly late-breaking initial azer-cel findings in progressive MS, alongside BRIUMVI trial updatesare driving attention. Traders see the late-breaking slot as encouraging but not proof of efficacy, while also looking ahead to Sub-Q trial results and speculating about a potential buyout.

A sharp Hims & Hers rally has revived breakout and short-covering chatter after months of choppy trading, though traders remain divided on whether the move can hold or will fade at resistance. Speculation about potential peptide access or regulatory changes is also cited as a possible catalyst, but no approval is confirmed.

Snowflakes stronger-than-expected quarterly results and raised outlook, attributed in part to accelerating AI-related demand and platform consumption, have driven a sharp rally. Traders are divided between seeing a durable AI growth reacceleration and warning that the valuation is stretched and the post-earnings surge may invite profit-taking.

UCO is drawing attention as traders react to volatile crude prices amid U.S.-Iran tensions and uncertainty over Strait of Hormuz shipping and oil supply. Supply-disruption fears support bullish oil positions, while hopes for diplomacy and increased supplies fuel bearish views; traders also question how closely the leveraged fund tracks oil moves.